IL6 and psoriasis: In contrast to antibodies against IL-6 or the IL-6 receptor, MHP1-AcN inhibited not only the expression of IL-6 but also IL-23, which emerged as an attractive therapeutic target for moderate-to severe psoriasis by using anti-IL-23 antibodies, such as guselkumab, tildrakizumab and risankizumab7.